Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Oil and Gas Photographer / Shutterstock.com Indonesia Energy (NYSEMKT: INDO ) stock is rising higher on Tuesday alongside the increasing price of natural gas . And it’s not a small increase, ei...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Wirestock Creators / Shutterstock.com Ocugen (NASDAQ: OCGN ) stock is gaining on Tuesday after Mizuho Securities analysts initiated coverage of the medical company’s shares. That coverage starts...
Mizuho Securities launched its coverage on COVID-19 vaccine developer Ocugen ( NASDAQ: OCGN ) with a Buy rating on Tuesday, citing a favorable risk/reward profile ahead of a key data readout for the company’s eye disease candidate OCU400. While investors have focuse...
Buying stocks shouldn't be like buying lottery tickets, but sometimes it can make sense to bet on a long shot. On that note, Ocugen (NASDAQ: OCGN) stock is down by more than 65% this year as the small biotech has struggled to commercialize a coronavirus vaccine. But could that j...
Commission-free trading platform Robinhood Markets grew in prominence helping newer investors participate in what remains one of the best ways to accumulate wealth over time. The initiative seems like a good one in principle. And to make matters more interesting, Robinhood offers a peek...
MALVERN, Pa., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, announced that Dr. Shankar Mu...
Second Quarter Reflects Increases In Pipeline Activity. Ocugen reported a loss of $19.5 million or $(0.09) per share, greater than our estimated loss of $16.7 million or $(0.07) per share. The difference was due to higher expenses from clinical trials and increased headcount as the company add...
Image source: The Motley Fool. Ocugen, Inc. (NASDAQ: OCGN) Q2 2022 Earnings Call Aug 05, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Ocugen, Inc. (OCGN) Q2 2022 Earnings Call Transcript
Ocugen, Inc. (OCGN) Q2 2022 Earnings Conference Call August 5, 2022 08:30 ET Company Participants Tiffany Hamilton - Head, Corporate Communications Shankar Musunuri - Chairman, Chief Executive Officer and Co-Founder Jessica Crespo - Chief Accounting Officer and S...
Ocugen press release ( NASDAQ: OCGN ): Q2 GAAP EPS of -$0.09 misses by $0.01 . The Company’s cash, cash equivalents, and restricted cash totaled $115.0 million as of June 30, 2022, compared to $95.1 million as of December 31, 2021. The Company believes that its ...
News, Short Squeeze, Breakout and More Instantly...
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and va...
2024-07-11 08:45:00 ET It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF , is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain. Of course, it's not hard to find stocks that have...